Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
KRYSTAL-7
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT04613596 ↗
- Recruiting
- Mirati Therapeutics Inc.
- Deep
We haven't built an HCP commentary report on KRYSTAL-7 (adagrasib and pembrolizumab in Advanced Non-Small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KRYSTAL-7 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 68 | |
| YouTube | 12 | |
| Podcasts | 11 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
- Phase
- Phase 2/Phase 3
- Status
- Recruiting
- Conditions
- Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer
- Interventions
- Adagrasib; Adagrasib; Adagrasib; Adagrasib; Pembrolizumab
- Arms
- Phase 2 Cohort 1a: PD-L1 TPS <1% · Experimental
- Phase 2 Cohort 1b: PD-L1 TPS <1% · Experimental
- Phase 2 Cohort 2: PD-L1 TPS ≥1% · Experimental
- Phase 3 Cohort 3 Investigational Arm · Experimental
- Phase 3 Cohort 4 Comparator Arm · Active comparator
- Enrollment
- 626 (estimated)
- Primary outcomes
- Phase 2: To evaluate the efficacy of Adagrasib monotherapy and in combination with pembrolizumab administered to patients having advanced/metastatic NSCLC.
- Phase 3: To compare efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumab
- Sponsor
- Mirati Therapeutics Inc.
- Start
- Dec 2, 2020
- Primary completion
- Oct 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04613596 · updated Oct 13, 2026